nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—CYP2C18—Dapsone—leprosy	0.135	0.153	CbGbCtD
Cyclophosphamide—CYP2A6—Rifampicin—leprosy	0.0796	0.0903	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Rifampicin—leprosy	0.0544	0.0617	CbGbCtD
Cyclophosphamide—CYP3A7—Rifampicin—leprosy	0.0544	0.0617	CbGbCtD
Cyclophosphamide—CYP2B6—Rifampicin—leprosy	0.0518	0.0588	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Dapsone—leprosy	0.0449	0.051	CbGbCtD
Cyclophosphamide—CYP3A7—Dapsone—leprosy	0.0449	0.051	CbGbCtD
Cyclophosphamide—CYP3A5—Thalidomide—leprosy	0.0422	0.0478	CbGbCtD
Cyclophosphamide—CYP3A5—Rifampicin—leprosy	0.0408	0.0463	CbGbCtD
Cyclophosphamide—CYP2C8—Rifampicin—leprosy	0.0393	0.0445	CbGbCtD
Cyclophosphamide—CYP2C19—Thalidomide—leprosy	0.034	0.0386	CbGbCtD
Cyclophosphamide—CYP3A5—Dapsone—leprosy	0.0337	0.0382	CbGbCtD
Cyclophosphamide—CYP2C19—Rifampicin—leprosy	0.0329	0.0374	CbGbCtD
Cyclophosphamide—CYP2C8—Dapsone—leprosy	0.0324	0.0368	CbGbCtD
Cyclophosphamide—CYP2C9—Thalidomide—leprosy	0.0283	0.0321	CbGbCtD
Cyclophosphamide—CYP2C9—Rifampicin—leprosy	0.0274	0.0311	CbGbCtD
Cyclophosphamide—CYP2C19—Dapsone—leprosy	0.0272	0.0308	CbGbCtD
Cyclophosphamide—ABCB1—Rifampicin—leprosy	0.0266	0.0301	CbGbCtD
Cyclophosphamide—CYP2C9—Dapsone—leprosy	0.0226	0.0256	CbGbCtD
Cyclophosphamide—CYP3A4—Rifampicin—leprosy	0.0159	0.0181	CbGbCtD
Cyclophosphamide—CYP3A4—Dapsone—leprosy	0.0131	0.0149	CbGbCtD
Cyclophosphamide—Myxoedema—Thalidomide—leprosy	0.0116	0.0979	CcSEcCtD
Cyclophosphamide—Toxic skin eruption—Thalidomide—leprosy	0.00574	0.0486	CcSEcCtD
Cyclophosphamide—Posterior reversible encephalopathy syndrome—Thalidomide—leprosy	0.00508	0.043	CcSEcCtD
Cyclophosphamide—Myelodysplastic syndrome—Thalidomide—leprosy	0.00415	0.0351	CcSEcCtD
Cyclophosphamide—Swelling face—Dapsone—leprosy	0.00342	0.0289	CcSEcCtD
Cyclophosphamide—Tumour lysis syndrome—Thalidomide—leprosy	0.003	0.0254	CcSEcCtD
Cyclophosphamide—Acute leukaemia—Thalidomide—leprosy	0.00292	0.0247	CcSEcCtD
Cyclophosphamide—Septic shock—Thalidomide—leprosy	0.00276	0.0234	CcSEcCtD
Cyclophosphamide—Thromboembolism—Thalidomide—leprosy	0.00262	0.0222	CcSEcCtD
Cyclophosphamide—Polyneuropathy—Thalidomide—leprosy	0.00256	0.0216	CcSEcCtD
Cyclophosphamide—Rales—Thalidomide—leprosy	0.00203	0.0172	CcSEcCtD
Cyclophosphamide—Dysaesthesia—Thalidomide—leprosy	0.00193	0.0163	CcSEcCtD
Cyclophosphamide—Pericarditis—Thalidomide—leprosy	0.00193	0.0163	CcSEcCtD
Cyclophosphamide—Ascites—Thalidomide—leprosy	0.00183	0.0155	CcSEcCtD
Cyclophosphamide—Embolism venous—Thalidomide—leprosy	0.00165	0.014	CcSEcCtD
Cyclophosphamide—Venous thrombosis—Thalidomide—leprosy	0.00154	0.0131	CcSEcCtD
Cyclophosphamide—Inappropriate antidiuretic hormone secretion—Thalidomide—leprosy	0.00143	0.0121	CcSEcCtD
Cyclophosphamide—Blood lactate dehydrogenase increased—Thalidomide—leprosy	0.00143	0.0121	CcSEcCtD
Cyclophosphamide—Platelet count decreased—Thalidomide—leprosy	0.0014	0.0119	CcSEcCtD
Cyclophosphamide—Febrile neutropenia—Thalidomide—leprosy	0.00138	0.0117	CcSEcCtD
Cyclophosphamide—Embolism—Thalidomide—leprosy	0.0013	0.011	CcSEcCtD
Cyclophosphamide—Nail disorder—Thalidomide—leprosy	0.00128	0.0109	CcSEcCtD
Cyclophosphamide—Neuralgia—Thalidomide—leprosy	0.0012	0.0102	CcSEcCtD
Cyclophosphamide—Thrombosis—Thalidomide—leprosy	0.00118	0.00996	CcSEcCtD
Cyclophosphamide—Hepatomegaly—Thalidomide—leprosy	0.00118	0.00996	CcSEcCtD
Cyclophosphamide—Interstitial lung disease—Thalidomide—leprosy	0.00118	0.00996	CcSEcCtD
Cyclophosphamide—Cholestasis—Thalidomide—leprosy	0.0011	0.00929	CcSEcCtD
Cyclophosphamide—Pleural effusion—Thalidomide—leprosy	0.00109	0.00921	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Dapsone—leprosy	0.00106	0.00894	CcSEcCtD
Cyclophosphamide—Amenorrhoea—Thalidomide—leprosy	0.000948	0.00803	CcSEcCtD
Cyclophosphamide—Viral infection—Thalidomide—leprosy	0.000922	0.00781	CcSEcCtD
Cyclophosphamide—Hyperbilirubinaemia—Thalidomide—leprosy	0.000916	0.00776	CcSEcCtD
Cyclophosphamide—Drug interaction—Thalidomide—leprosy	0.000898	0.0076	CcSEcCtD
Cyclophosphamide—Hyperuricaemia—Thalidomide—leprosy	0.000898	0.0076	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Dapsone—leprosy	0.000892	0.00755	CcSEcCtD
Cyclophosphamide—Hearing impaired—Thalidomide—leprosy	0.000875	0.00741	CcSEcCtD
Cyclophosphamide—Blood uric acid increased—Thalidomide—leprosy	0.000848	0.00718	CcSEcCtD
Cyclophosphamide—Pulmonary embolism—Thalidomide—leprosy	0.000833	0.00705	CcSEcCtD
Cyclophosphamide—Hyperkalaemia—Thalidomide—leprosy	0.000819	0.00693	CcSEcCtD
Cyclophosphamide—Colitis—Thalidomide—leprosy	0.0008	0.00677	CcSEcCtD
Cyclophosphamide—Tinnitus—Dapsone—leprosy	0.000762	0.00645	CcSEcCtD
Cyclophosphamide—Pulmonary oedema—Thalidomide—leprosy	0.000742	0.00628	CcSEcCtD
Cyclophosphamide—Sepsis—Thalidomide—leprosy	0.000723	0.00612	CcSEcCtD
Cyclophosphamide—Erythema—Dapsone—leprosy	0.000711	0.00602	CcSEcCtD
Cyclophosphamide—Diabetes mellitus—Thalidomide—leprosy	0.000695	0.00589	CcSEcCtD
Cyclophosphamide—Gastroenteritis—Thalidomide—leprosy	0.000682	0.00578	CcSEcCtD
Cyclophosphamide—Deafness—Thalidomide—leprosy	0.000676	0.00572	CcSEcCtD
Cyclophosphamide—Vision blurred—Dapsone—leprosy	0.000671	0.00568	CcSEcCtD
Cyclophosphamide—Cardiac failure congestive—Thalidomide—leprosy	0.000667	0.00565	CcSEcCtD
Cyclophosphamide—Renal failure acute—Thalidomide—leprosy	0.000655	0.00555	CcSEcCtD
Cyclophosphamide—Atrial fibrillation—Thalidomide—leprosy	0.000638	0.0054	CcSEcCtD
Cyclophosphamide—Dermatitis bullous—Thalidomide—leprosy	0.000633	0.00536	CcSEcCtD
Cyclophosphamide—Cough—Dapsone—leprosy	0.000621	0.00526	CcSEcCtD
Cyclophosphamide—Cardiac failure—Thalidomide—leprosy	0.00062	0.00525	CcSEcCtD
Cyclophosphamide—Hyponatraemia—Thalidomide—leprosy	0.000607	0.00514	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.000605	0.00512	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Thalidomide—leprosy	0.000575	0.00487	CcSEcCtD
Cyclophosphamide—Tachycardia—Dapsone—leprosy	0.000567	0.0048	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Thalidomide—leprosy	0.000545	0.00461	CcSEcCtD
Cyclophosphamide—Bronchospasm—Thalidomide—leprosy	0.000514	0.00435	CcSEcCtD
Cyclophosphamide—Pancytopenia—Thalidomide—leprosy	0.000496	0.0042	CcSEcCtD
Cyclophosphamide—Weight increased—Thalidomide—leprosy	0.000476	0.00403	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Thalidomide—leprosy	0.000472	0.00399	CcSEcCtD
Cyclophosphamide—Pneumonia—Thalidomide—leprosy	0.000469	0.00397	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Thalidomide—leprosy	0.000462	0.00391	CcSEcCtD
Cyclophosphamide—Acute coronary syndrome—Thalidomide—leprosy	0.000459	0.00389	CcSEcCtD
Cyclophosphamide—Body temperature increased—Dapsone—leprosy	0.000459	0.00389	CcSEcCtD
Cyclophosphamide—Renal failure—Thalidomide—leprosy	0.000458	0.00388	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Thalidomide—leprosy	0.000457	0.00387	CcSEcCtD
Cyclophosphamide—Myocardial infarction—Thalidomide—leprosy	0.000457	0.00387	CcSEcCtD
Cyclophosphamide—Stomatitis—Thalidomide—leprosy	0.000454	0.00385	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Thalidomide—leprosy	0.000453	0.00384	CcSEcCtD
Cyclophosphamide—Sweating—Thalidomide—leprosy	0.000447	0.00378	CcSEcCtD
Cyclophosphamide—Haematuria—Thalidomide—leprosy	0.000444	0.00376	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Thalidomide—leprosy	0.000435	0.00368	CcSEcCtD
Cyclophosphamide—Bradycardia—Thalidomide—leprosy	0.000426	0.00361	CcSEcCtD
Cyclophosphamide—Rhinitis—Thalidomide—leprosy	0.000419	0.00355	CcSEcCtD
Cyclophosphamide—Hepatitis—Thalidomide—leprosy	0.000418	0.00354	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Thalidomide—leprosy	0.000416	0.00352	CcSEcCtD
Cyclophosphamide—Visual impairment—Thalidomide—leprosy	0.000403	0.00341	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Thalidomide—leprosy	0.000396	0.00335	CcSEcCtD
Cyclophosphamide—Tinnitus—Thalidomide—leprosy	0.00039	0.0033	CcSEcCtD
Cyclophosphamide—Chills—Thalidomide—leprosy	0.000375	0.00318	CcSEcCtD
Cyclophosphamide—Arrhythmia—Thalidomide—leprosy	0.000374	0.00316	CcSEcCtD
Cyclophosphamide—Alopecia—Thalidomide—leprosy	0.00037	0.00313	CcSEcCtD
Cyclophosphamide—Vomiting—Dapsone—leprosy	0.000369	0.00313	CcSEcCtD
Cyclophosphamide—Headache—Dapsone—leprosy	0.000364	0.00308	CcSEcCtD
Cyclophosphamide—Dysgeusia—Thalidomide—leprosy	0.000357	0.00302	CcSEcCtD
Cyclophosphamide—Muscle spasms—Thalidomide—leprosy	0.00035	0.00296	CcSEcCtD
Cyclophosphamide—Nausea—Dapsone—leprosy	0.000345	0.00292	CcSEcCtD
Cyclophosphamide—Vision blurred—Thalidomide—leprosy	0.000343	0.00291	CcSEcCtD
Cyclophosphamide—Tremor—Thalidomide—leprosy	0.000341	0.00289	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Thalidomide—leprosy	0.000338	0.00286	CcSEcCtD
Cyclophosphamide—Anaemia—Thalidomide—leprosy	0.000337	0.00285	CcSEcCtD
Cyclophosphamide—Agitation—Thalidomide—leprosy	0.000335	0.00283	CcSEcCtD
Cyclophosphamide—Malaise—Thalidomide—leprosy	0.000328	0.00278	CcSEcCtD
Cyclophosphamide—Leukopenia—Thalidomide—leprosy	0.000326	0.00276	CcSEcCtD
Cyclophosphamide—Palpitations—Thalidomide—leprosy	0.000322	0.00272	CcSEcCtD
Cyclophosphamide—Cough—Thalidomide—leprosy	0.000318	0.00269	CcSEcCtD
Cyclophosphamide—Convulsion—Thalidomide—leprosy	0.000316	0.00267	CcSEcCtD
Cyclophosphamide—Hypertension—Thalidomide—leprosy	0.000314	0.00266	CcSEcCtD
Cyclophosphamide—Chest pain—Thalidomide—leprosy	0.00031	0.00262	CcSEcCtD
Cyclophosphamide—Arthralgia—Thalidomide—leprosy	0.00031	0.00262	CcSEcCtD
Cyclophosphamide—Myalgia—Thalidomide—leprosy	0.00031	0.00262	CcSEcCtD
Cyclophosphamide—Discomfort—Thalidomide—leprosy	0.000306	0.00259	CcSEcCtD
Cyclophosphamide—Confusional state—Thalidomide—leprosy	0.0003	0.00254	CcSEcCtD
Cyclophosphamide—Oedema—Thalidomide—leprosy	0.000297	0.00252	CcSEcCtD
Cyclophosphamide—Infection—Thalidomide—leprosy	0.000295	0.0025	CcSEcCtD
Cyclophosphamide—Shock—Thalidomide—leprosy	0.000292	0.00248	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Thalidomide—leprosy	0.000291	0.00246	CcSEcCtD
Cyclophosphamide—Tachycardia—Thalidomide—leprosy	0.00029	0.00246	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Thalidomide—leprosy	0.000287	0.00243	CcSEcCtD
Cyclophosphamide—Anorexia—Thalidomide—leprosy	0.000283	0.0024	CcSEcCtD
Cyclophosphamide—Hypotension—Thalidomide—leprosy	0.000278	0.00235	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Thalidomide—leprosy	0.000271	0.00229	CcSEcCtD
Cyclophosphamide—Paraesthesia—Thalidomide—leprosy	0.000267	0.00226	CcSEcCtD
Cyclophosphamide—Dyspnoea—Thalidomide—leprosy	0.000265	0.00224	CcSEcCtD
Cyclophosphamide—Decreased appetite—Thalidomide—leprosy	0.000258	0.00219	CcSEcCtD
Cyclophosphamide—Fatigue—Thalidomide—leprosy	0.000256	0.00217	CcSEcCtD
Cyclophosphamide—Constipation—Thalidomide—leprosy	0.000254	0.00215	CcSEcCtD
Cyclophosphamide—Pain—Thalidomide—leprosy	0.000254	0.00215	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Thalidomide—leprosy	0.000245	0.00207	CcSEcCtD
Cyclophosphamide—Urticaria—Thalidomide—leprosy	0.000236	0.002	CcSEcCtD
Cyclophosphamide—Body temperature increased—Thalidomide—leprosy	0.000235	0.00199	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Thalidomide—leprosy	0.000219	0.00185	CcSEcCtD
Cyclophosphamide—Asthenia—Thalidomide—leprosy	0.000213	0.00181	CcSEcCtD
Cyclophosphamide—Pruritus—Thalidomide—leprosy	0.00021	0.00178	CcSEcCtD
Cyclophosphamide—Diarrhoea—Thalidomide—leprosy	0.000203	0.00172	CcSEcCtD
Cyclophosphamide—Dizziness—Thalidomide—leprosy	0.000197	0.00166	CcSEcCtD
Cyclophosphamide—Vomiting—Thalidomide—leprosy	0.000189	0.0016	CcSEcCtD
Cyclophosphamide—Rash—Thalidomide—leprosy	0.000187	0.00159	CcSEcCtD
Cyclophosphamide—Dermatitis—Thalidomide—leprosy	0.000187	0.00159	CcSEcCtD
Cyclophosphamide—Headache—Thalidomide—leprosy	0.000186	0.00158	CcSEcCtD
Cyclophosphamide—Nausea—Thalidomide—leprosy	0.000177	0.00149	CcSEcCtD
